Guardant touts data presented at SABCS

By staff writers

December 7, 2020 -- Guardant Health has touted research presented at the 2020 virtual San Antonio Breast Cancer Symposium (SABCS) demonstrating how its tools benefit women with breast cancer and advance breast cancer research.

Three research abstracts presented at the conference utilized Guardant's technology:

  1. Abstract PS18-15 demonstrated the heterogeneity of ESR1 mutations associated with endocrine therapy treatment using data from the Guardant360 liquid biopsy dataset
  2. Abstract PS18-28 utilized GuardantInform to identify a potential new mechanism of acquired treatment resistance among women with breast cancer treated with CDK4/6 inhibitors
  3. Abstract OT-07-01 highlighted Guardant360 as a tool to provide a more comprehensive view of the medical records and clinical journeys of patients with breast cancer

In particular, the company pointed to the new research showing its GuardantInform platform identified treatment resistance in some patients with metastatic breast cancer. GuarantInform is a clinical-genomic platform designed to support more effective cancer therapies by combining de-identified clinical information with genomic data from the Guardant360 liquid biopsy test, according to Guardant.

The new research utilizing the platform showed patients with estrogen-receptor positive (ER-positive) and HER-2 negative metastatic breast cancer experienced treatment resistance. The tool can also be used targeted drug development, clinical trial optimization, and postmarketing studies, Guardant noted.

Top companies earn 80% of revenue in IVD market
Most of the revenue in the IVD market is generated by fewer than 20 companies, according to a recent report by IVD market research firm Kalorama Information,...
FDA approves Guardant's liquid biopsy NGS test
The U.S. Food and Drug Administration (FDA) has approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS)...
Seoul researchers tout Guardant360 clinical results
South Korean researchers highlighted clinical results from a study that used precision oncology company Guardant Health's Guardant360 test in patients...
TMB test predicts immunotherapy effects in lung cancer patients
The level of tumor mutational burden (TMB) in blood appears to be an effective biomarker for gauging response to immunotherapies and survival in patients...
Liquid biopsy test detects biomarker for immunotherapy
Precision oncology company Guardant Health is touting a new study confirming that its Guardant360 liquid biopsy test can accurately detect microsatellite...

Copyright © 2020

Last Updated ls 12/7/2020 5:19:06 PM